{
  "id": "fda_guidance_chunk_0305",
  "title": "Introduction - Part 305",
  "text": "that tests remain adequate throughout the trial period (see 8.2.12) X (where required) X 8.3.8 DOCUMENTATION OF INVESTIGATIONAL PRODUCT(S) AND TRIAL-RELATED MATERIALS SHIPMENT (See 8.2.15) X X 8.3.9 CERTIFICATE(S) OF ANALYSIS FOR NEW BATCHES OF INVESTIGATIONAL PRODUCTS (See 8.2.16) X 8.3.10 MONITORING VISIT REPORTS To document site visits by, and findings of, the monitor X Contains Nonbinding Recommendations 8.3.11 RELEVANT COMMUNICATIONS OTHER THAN SITE VISITS -Letters -Meeting notes -Notes of telephone calls To document any agreements or significant discussions regarding trial administration, protocol violations, trial conduct, adverse event (AE) reporting X X 8.3.12 SIGNED INFORMED CONSENT FORMS To document that consent is obtained in accordance with GCP and protocol and dated prior to participation of each subject in trial. Also to document direct access permission (see 8.2.3) X 8.3.13 SOURCE DOCUMENTS To document the existence of the subject and substantiate integrity of trial data collected. To include original documents related to the trial, to medical treatment, and history of subject X 8.3.14 SIGNED, DATED, AND COMPLETED CASE REPORT FORMS (CRF) To document that the investigator or authorized member of the investigatorâ€™s staff confirms the observations recorded X (copy) X (original) 8.3.15 DOCUMENTATION OF CRF CORRECTIONS To document all changes/additions or corrections made to CRF after initial data were recorded X (copy) X (original) 8.3.16 NOTIFICATION BY ORIGINATING INVESTIGATOR TO SPONSOR OF SERIOUS ADVERSE EVENTS AND RELATED REPORTS Notification by originating investigator to sponsor of serious adverse events and related reports in accordance X X Contains Nonbinding Recommendations with 4.11 8.3.17 NOTIFICATION BY SPONSOR AND/OR INVESTIGATOR, WHERE APPLICABLE, TO REGULATORY AUTHORITY(IES) AND IRB(S)/IEC(S) OF UNEXPECTED SERIOUS ADVERSE DRUG REACTIONS AND OF OTHER SAFETY INFORMATION Notification by sponsor and/or investigator, where applicable, to regulatory authorities and IRB(s)/IEC(s) of unexpected serious adverse drug reactions in accordance with 5.17 and 4.11.1 and of other safety information in accordance with 5.16.2 and 4.11.2 X (where required) X 8.3.18 NOTIFICATION BY SPONSOR TO INVESTIGATORS OF SAFETY INFORMATION Notification by sponsor to investigators of safety information in accordance with 5.16.2 X X 8.3.19 INTERIM OR ANNUAL REPORTS TO IRB/IEC AND AUTHORITY(IES) Interim or annual reports provided to IRB/IEC in accordance with 4.10 and to authority(ies) in accordance with 5.17.3 X X (where required) 8.3.20 SUBJECT SCREENING LOG To document identification of subjects who entered pre-trial screening X X (where required) 8.3.21",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 408576,
  "end_pos": 410112,
  "tokens": 512,
  "tags": [
    "safety",
    "statistical",
    "clinical_trial",
    "consent",
    "data"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "mandatory",
  "created_at": "2025-10-23T02:25:44.699Z"
}